N.B. could reverse decision not to fund new RSV vaccine for seniors, health minister suggests

Health Minister Bruce Fitch says the province could revisit its decision not to cover the cost of the new RSV vaccine for seniors.

He was responding to criticism from Liberal Leader Susan Holt, who argues the province should fund the vaccine to keep seniors healthy, to ease the burden on hospitals and to save the health-care system money.

Holt raised the issue during question period Tuesday, following a CBC report.

"The best way to reduce the strain on our hospitals and ERs is to prevent people from showing up there in the first place," she said.

Yet residents in her riding of Bathurst East-Nepisiguit-Saint-Isidore, like senior Pat Flanagan of east Bathurst, who's on a fixed pension, she said, face a cost of nearly $300 for the vaccine against respiratory syncytial virus, or RSV.

This, despite the fact that RSV is "one of the main causes" why people end up in the hospital at this time of year, according to Holt.

The common respiratory virus causes a mild cold-like illness for most people but the Public Health Agency of Canada says it can be severe for people aged 65 and older, infants and people who are immunocompromised. It can result in hospitalization and even death.

Last fall and winter, New Brunswick recorded more than 1,500 RSV cases — the highest number in at least a decade.

Holt suggested the associated hospital costs amounted to more than $1.2 million. "We could provide vaccines to 4,000 seniors with that money instead of putting that burden on our nurses and doctors," she said.

Asked later by CBC how she arrived at that figure, since the province has no data on how many of those 1,500 people were hospitalized or for how long, she said it was a "just a generalization" based on one day of hospitalization each at a cost of roughly $800 per day.

"We can all agree that it costs New Brunswick more to provide care to a patient in the hospital for a day than the cost of this vaccine," Holt told the legislature.

"So I'm hoping [Fitch] would describe for me why they have considered and decided not to fund this vaccine for seniors who are struggling with affordability and interested in protecting their health."

Fitch said the government is aware of the impact RSV had on the province last year and of Health Canada's decision in August to approve Arexvy — the first RSV vaccine for people aged 60 and older.

"We don't need to take any lessons from the Opposition, but we also want to take the advice from the experts."